Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Early Management of CML
Author: Shanmuganathan, N.
Hughes, T.P.
Citation: Current Hematologic Malignancy Reports, 2019; 14(6):480-491
Publisher: Springer (part of Springer Nature)
Issue Date: 2019
ISSN: 1558-8211
Statement of
Naranie Shanmuganathan, Timothy P. Hughes
Abstract: PURPOSE OF REVIEW:The marked improvement in clinical outcomes for patients with chronic myeloid leukaemia (CML) can be solely attributed to the introduction of targeted therapies against the fusion oncoprotein, BCR-ABL1. However, patient responses, although generally positive, remain heterogenous. Careful drug selection, ensuring the optimal TKI, is chosen for each patient and involves a complex decision process which incorporates consideration of numerous factors. RECENT FINDINGS:For some patients, with disease characteristics that indicate adverse intrinsic disease biology, more potent BCR-ABL1 inhibition is often appropriate, whereas other patients with major co-morbidities will benefit from a less aggressive approach to avoid life-shortening toxicities. For the vast majority of patients, the long-term goal of therapy will be the achievement of a deep molecular response and subsequent treatment-free remission and this consideration will play a large part in the drug selection process. We explore early management of CML, from the first presentation through to frontline therapy selection.
Keywords: Deep molecular responses
Drug toxicity
Treatment-free remission
Rights: © Springer Science+Business Media, LLC, part of Springer Nature 2019.
DOI: 10.1007/s11899-019-00550-8
Grant ID:
Published version:
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.